Pharmaceutical Contract Manufacturing: A Comprehensive Guide to ...

What is Pharmaceutical Contract Manufacturing?

Pharmaceutical contract manufacturing is when pharmaceutical companies outsource drug production to specialized third-party manufacturers. These contract manufacturers, known as Contract Manufacturing Organizations (CMOs), provide comprehensive services ranging from drug formulation and production to packaging and distribution. This model allows pharmaceutical companies to leverage the expertise, infrastructure, and technology of CMOs without investing heavily in manufacturing facilities.

Goto TJCY to know more.

Contract manufacturing is widely used in the pharmaceutical industry, particularly by small and mid-sized firms that lack the resources to establish and maintain their production units. Even large pharmaceutical companies engage CMOs to optimize their supply chain, reduce costs, and accelerate time-to-market for new drugs.

With the increasing complexity of drug formulations, regulatory requirements, and demand for cost efficiency, pharmaceutical contract manufacturing has emerged as a strategic solution for companies focusing on research, development, and marketing while outsourcing production activities.

Pros & Cons of Pharmaceutical Contract Manufacturing

Pros

1. Cost Savings: One of the primary advantages of pharmaceutical contract manufacturing is cost efficiency. CMOs have established production facilities, eliminating the need for pharmaceutical companies to invest in expensive infrastructure, equipment, and regulatory compliance.
2. Access to Expertise: CMOs specialize in drug manufacturing and possess deep expertise in regulatory requirements, formulation development, and quality control, ensuring high production standards.
3. Scalability & Flexibility: Companies can scale production volumes up or down based on market demand without worrying about capacity constraints or underutilized manufacturing facilities.
4. Faster Time-to-Market: By outsourcing production, pharmaceutical companies can focus on drug research and development, accelerating the launch of new products.
5. Regulatory Compliance: Reputable CMOs comply with Good Manufacturing Practices (GMP) and other regulatory standards, reducing the risk of non-compliance issues for pharmaceutical companies.
6. Global Expansion: Pharmaceutical firms can leverage CMOs with an international presence to expand their reach into new markets without setting up local manufacturing units.

Cons

1. Loss of Control: Outsourcing production means relying on third-party manufacturers, which can lead to potential quality control issues and supply chain disruptions.
2. Intellectual Property (IP) Risks: Sharing proprietary formulations and processes with CMOs carries the risk of IP theft or unauthorized replication.
3. Regulatory Risks: If a CMO fails to meet regulatory standards, the pharmaceutical company may face legal and reputational risks.
4. Hidden Costs: While contract manufacturing offers cost savings, additional expenses related to quality assurance, audits, and regulatory oversight can arise.
5. Dependency on CMO Performance: If a contract manufacturer experiences production delays, quality issues, or financial instability, it can directly impact the pharmaceutical company’s supply chain and revenue.

Download the pdf brochure to learn about the assumptions considered for the study.

Types of Pharmaceutical Contract Manufacturing

Pharmaceutical contract manufacturing encompasses a variety of services tailored to meet different needs within the industry. The key types include:

1. Active Pharmaceutical Ingredients (API) Manufacturing

APIs are the core components of pharmaceutical drugs that produce therapeutic effects. Contract API manufacturers specialize in chemical synthesis, fermentation, or biotechnological methods to make these key ingredients. Due to stringent quality standards and regulatory oversight, many pharmaceutical companies outsource API production to experienced CMOs.

2. Finished Dosage Form (FDF) Manufacturing

This involves the production of the final drug product in the form of tablets, capsules, injections, or liquid formulations. Contract manufacturers offering FDF services handle everything from formulation development to large-scale commercial production, ensuring compliance with regulatory authorities such as the FDA and EMA.

3. Packaging & Labeling Services

Contract manufacturers also provide specialized packaging solutions, including blister packs, bottles, vials, and ampoules. They ensure compliance with labelling regulations, serialization, and anti-counterfeiting measures.

4. Lyophilization & Sterile Manufacturing

Some drugs, particularly biologics and injectables, require specialized manufacturing techniques such as lyophilization (freeze-drying) or aseptic processing. CMOs with expertise in sterile manufacturing provide facilities that meet stringent regulatory requirements.

5. Biopharmaceutical Manufacturing

The rise of biologics, including monoclonal antibodies, vaccines, and cell & gene therapies, has led to a demand for specialized contract manufacturing services. Biopharmaceutical CMOs offer expertise in bioprocessing, fermentation, and purification techniques.

6. Analytical & Regulatory Services

Many CMOs offer analytical testing, stability studies, and regulatory consulting to ensure that pharmaceutical products meet global regulatory standards. This helps companies navigate complex compliance requirements more effectively.

The Growth of the Pharmaceutical Contract Manufacturing Market

The global pharmaceutical contract manufacturing market is experiencing significant growth, driven by increasing demand for cost-effective drug production, outsourcing trends, and advancements in biologics.

• In , the market was valued at US$183.6 billion.
• By , it is projected to reach US$200.9 billion, reflecting a robust growth trajectory.
• By , the market is expected to hit US$319.6 billion, with an impressive CAGR of 9.7%.

Several factors are contributing to this expansion:

• Rising Demand for Biologics: The growing adoption of biopharmaceuticals is pushing pharmaceutical companies to collaborate with specialized contract manufacturers.
• Increasing Outsourcing by Pharma Giants: Leading pharmaceutical companies increasingly outsource manufacturing to focus on R&D and marketing strategies.
• Stringent Regulatory Requirements: CMOs with expertise in regulatory compliance are in high demand as pharmaceutical firms seek to meet rigorous global standards.
• Advancements in Manufacturing Technologies: Continuous innovation in drug formulation, nanotechnology, and automation is driving efficiency and scalability in contract manufacturing.

Download the pdf brochure to learn about the assumptions considered for the study.

Contact us to discuss your requirements of what is fdf in pharma. Our experienced sales team can help you identify the options that best suit your needs.

Conclusion

Pharmaceutical contract manufacturing has become vital to the global pharmaceutical industry, enabling companies to enhance efficiency, reduce costs, and accelerate product development. While it offers numerous advantages, including cost savings, expertise access, and scalability, it also presents challenges such as dependency on third-party manufacturers and regulatory risks.

As the market grows rapidly, pharmaceutical companies must strategically choose the right CMOs to ensure product quality, regulatory compliance, and long-term success. With the industry projected to reach US$319.6 billion by , pharmaceutical contract manufacturing will remain a key driver of innovation and efficiency in the healthcare sector.

Related Reports:

Do you require Stability Testing services, also known as Shelf-life Studies, for the registration of a new Drug Substance (Active Pharmaceutical Ingredient, API) or Drug Product (Finished Dosage Form, FDF)? Or do you have any questions on what stability tests are required for your project to meet the highest international quality standards?

Eurofins BioPharma Product Testing Netherlands (“EBPT-NL”) can be your complete outsourcing partner to register your product for various international markets. Our WHO-prequalified and EU-GMP accredited laboratories in the Netherlands, are fully equipped for stability testing compliant with the pharmacopoeia and in line with ICH conditions (listed below).

Standard ICH Compliant Stability 

One of our core businesses is to determine the quality of your pharmaceutical substance. Our five laboratories are well equipped to perform all necessary standard stability studies like:

• Regular and on-going stability testing
• Fully controlled climate conditions (chamber and cabinets)
• Extractable and Leachable testing
• Forced degradation and Photostability studies
• Holding time studies
• In-use stability testing
• Freeze-thaw stability testing

ICH Conditions

EBPT-NL houses walk-in rooms for the most common climate zones, i.e. long-term (25H60), intermediate (30H65) and accelerated (40H75). For other ICH conditions climate cabinets are available. All rooms and cabinets are continuously monitored by automated monitoring systems with full back-up of data and power supply. The available conditions are listed hereunder.

• ≤ - 60 °C (Deep Frozen)
• - 20 ± 3 °C (Frozen)
• 5 ± 3 °C (Refrigerated, Accelerated Frozen)
• 15 ± 3 °C
• 25 ± 2 °C / 40 ± 5 % RH
• 25 ± 2 °C / 60 ± 5 % RH (ICH Zone II, Accelerated Refrigerated)
• 30 ± 2 °C / 65 ± 5 % RH (ICH Zone IVa, Intermediate)
• 30 ± 2 °C / 70 ± 5 % RH
• 30 ± 2 °C / 75 ± 5 % RH (ICH Zone IVb)
• 40 ± 2 °C / 75 ± 5 % RH (Accelerated Ambient) 

Regular and On-Going Stability

Regular stability studies do not need more elaboration than stating that EBPT-NL executes those on pivotal (clinical trial medication) and commercial batches. On-Going studies are executed on commercial batches only, namely one batch per annum per product.

In-Use Stability

In-Use stability studies are typically executed on multi-dose products such as topical (gels, creams, lotions, etc.), eye and ear drops and oral liquids. An In-Use study is mostly run in parallel with a Regular stability study, i.e. at one or multiple time points of the Regular study an In-Use study starts whereby the time point of the Regular study (e.g. 6 months) serves as the initial time point for the In-Use study. The In-Use study typically lasts several days or weeks. 

Freeze-Thaw Stability

During transportation of a product it is not uncommon that it is subjected to extreme temperature conditions such as freezing or overheating. For some products it is necessary to be able to withstand a certain degree of temperature change during transport.

Freeze-Thaw studies put products through a series of extreme temperature changes, the so-called freeze-thaw cycles. An example of a freeze-thaw cycle is exposing the product to freezing temperatures (approximately -15°C to -25°C) for 24 hours and then store it at a higher temperature (approximately 25°C) for 24 hours. The sample is then analysed for significant changes. This completes one cycle. If no significant changes are observed after three cycles one can be confident that the product is sufficiently stable for transport. 

Forced Degradation and Photostability

Forced degradation studies, also known as stress testing, play a central role in formulation development, manufacturability assessment and development of stability-indicating analytical test methods. A stability-indicating method is a method that accurately and precisely measures a drug substance or drug product well separated from process impurities, excipients and degradation products. Stress tests generate representative samples to assess drug substance and drug product stability, provide information about possible degradation pathways and demonstrate the stability-indicating power of the analytical procedures applied.

The execution of a Forced Degradation Study routinely includes treatment of samples with acid, base, peroxide, temperature and light. Other conditions can be added upon request or after evaluation of the first results.

For the application of light a specific cabinet is used that imitates sunlight and adheres to ICH Guideline Q1B. This cabinet and guideline are also in Photostability Studies, i.e. studies to assess the light sensitivity of API’s or FDF’s.  

If you require advice on your stability program, the various types of stability studies or more information on our stability storage capacity then please contact us.

Are you interested in learning more about api intermediates meaning? Contact us today to secure an expert consultation!

Why choose Eurofins BioPharma Product Testing Netherlands?